Companies › A2A Pharmaceuticals
1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AO-252 TACC3 protein-protein interaction (PPI) inhibitor | TACC3 | Phase 1 | Solid Tumor Malignancies | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06136884 | AO-252 | Phase 1 | Solid Tumor Malignancies | Oncology | Jan 2027 |
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.